Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.74 |
| ▸ | MAPK13 | O15264 | 17/20 | 0.74 |
| ▸ | MAPK12 | P53778 | 17/20 | 0.74 |
| ▸ | MAPK11 | Q15759 | 17/20 | 0.74 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.70 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.70 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.70 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.70 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.70 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.70 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.70 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.64 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.62 |
| ▸ | FRK | P42685 | 1/20 | 0.62 |
| ▸ | GSK3B | P49841 | 1/20 | 0.62 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1127929 | 1.00 | MAPK14 (0.74) | MAPK14MAPK13MAPK12MAPK11MAP4K4 | |
| SCHEMBL27353309 | 0.89 | MAPK14 (0.83) | MAPK14MAPK13MAPK12MAPK11MAP4K4 | |
| SCHEMBL5564280 | 0.87 | MAPK14 (0.83) | MAPK14MAPK13MAPK12MAPK11MAP4K4 | |
| SCHEMBL8860245 | 0.85 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11MAP4K4 | |
| SCHEMBL4913405 | 0.85 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11MAP4K4 | |
| SCHEMBL4907633 | 0.85 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11MAP4K4 | |
| SCHEMBL27353308 | 0.85 | MAPK14 (0.61) | MAPK14MAPK13MAPK12MAPK11MAP4K4 | |
| SCHEMBL4915616 | 0.84 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11MAP4K4 | |
| SCHEMBL4912942 | 0.84 | MAPK13 (0.79) | MAPK14MAPK13MAPK12MAPK11MAP4K4 | |
| SCHEMBL7090722 | 0.83 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127723-A1 | TREATMENT OF PLURIPOTENT CELLS | JANSSEN BIOTECH, INC. (US) | 2018-05-10 | — | — | US | disclosed |
| EP-2664669-B1 | TREATMENT OF PLURIPOTENT CELLS | JANSSEN BIOTECH INC (US) | 2017-12-27 | — | — | EP | disclosed |
| US-9845460-B2 | Treatment of pluripotent cells | JANSSEN BIOTECH, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-20140080210-A1 | Treatment of Pluripotent Cells | JANSSEN BIOTECH, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8623648-B2 | Treatment of pluripotent cells | JANSSEN BIOTECH, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| EP-2664669-A1 | Treatment of pluripotent cells | Janssen Biotech, Inc. (US) | 2013-11-20 | — | — | EP | disclosed |
| EP-2283114-A2 | TREATMENT OF PLURIPOTENT CELLS | Centocor Ortho Biotech Inc. (US) | 2011-02-16 | — | — | EP | disclosed |
| US-20090325293-A1 | TREATMENT OF PLURIPOTENT CELLS | JANSSEN BIOTECH, INC. | 2009-12-31 | — | — | US | disclosed |
| WO-2009132068-A2 | TREATMENT OF PLURIPOTENT CELLS | CENTOCOR ORTHO BIOTECH INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| CN-1211381-C | Substituted imidazoles useful in treatment of inflammatory diseases | ORTHO MCNEIL CORP INC (US) | 2005-07-20 | — | — | CN | disclosed |
| EP-1028954-B1 | SUBSTITUTED IMIDAZOLES USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | ORTHO MCNEIL PHARM INC (US) | 2003-07-02 | — | — | EP | disclosed |
| EP-1028954-A1 | SUBSTITUTED IMIDAZOLES USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2000-08-23 | — | — | EP | disclosed |
| CN-1253558-A | Substituted imidazoles useful in treatment of inflammatory diseases | ORTHO MCNEIL CORP INC (US) | 2000-05-17 | — | — | CN | disclosed |
| US-5965583-A | ANTIINFLAMMATORY AGENTS IN THE TREATMENT OF DISEASES ASSOCIATED WITH OVERPRODUCTION OF INFLAMMATORY CYTOKINES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 1999-10-12 | — | — | US | disclosed |
| WO-1998047892-A1 | SUBSTITUTED IMIDAZOLES USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | ORTHO-MCNEIL CORPORATION, INC. (US) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127723-A1 | TREATMENT OF PLURIPOTENT CELLS | GSK3B, GSK3A, GSKIP | MAPK14 2384/4885MAPK13 2812/4885MAPK12 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.